Loading…

Improvement of the synthetic tri-peptide vaccine (S3Pvac) against porcine Taenia solium cysticercosis in search of a more effective, inexpensive and manageable vaccine

Abstract Vaccination of pigs may curtail Taenia solium transmission by reducing the number of cysticerci, the precursors of adult intestinal tapeworms in humans. Several antigen preparations induce protection against porcine cysticercosis in experimental settings but only one subunit vaccine (S3Pvac...

Full description

Saved in:
Bibliographic Details
Published in:Vaccine 2007-02, Vol.25 (8), p.1368-1378
Main Authors: Sciutto, Edda, Rosas, Gabriela, Hernández, Marisela, Morales, Julio, Cruz-Revilla, Carmen, Toledo, Andrea, Manoutcharian, Karen, Gevorkian, Goar, Blancas, Abel, Acero, Gonzalo, Hernández, Beatriz, Cervantes, Jacquelynne, Bobes, Raul J, Goldbaum, Fernando A, Huerta, Mirna, Diaz-Orea, Alicia, Fleury, Agnes, de Aluja, Aline S, Cabrera-Ponce, Jose Luis, Herrera-Estrella, Luis, Fragoso, Gladis, Larralde, Carlos
Format: Article
Language:English
Subjects:
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Vaccination of pigs may curtail Taenia solium transmission by reducing the number of cysticerci, the precursors of adult intestinal tapeworms in humans. Several antigen preparations induce protection against porcine cysticercosis in experimental settings but only one subunit vaccine (S3Pvac) has been tested and proved effective in the field against naturally acquired disease. Besides improving of the vaccine's effectiveness, significant reductions in production costs and in the logistics of its administration are necessary for the feasibility of nationwide control programs. This review highlights the development of several versions of S3Pvac aimed to increase effectiveness, reduce costs and increase feasibility by novel delivery systems and alternative routes of administration.
ISSN:0264-410X
1873-2518
DOI:10.1016/j.vaccine.2006.10.018